Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) Scientific advisory board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44

Article  CAS  PubMed  Google Scholar 

Nishiyama KK, Cohen A, Young P, Wang J, Lappe JM, Guo XE, Dempster DW, Recker RR, Shane E (2014) Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab 99:2418–2425

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321

Article  CAS  PubMed  Google Scholar 

Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1–84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929–940

Article  CAS  PubMed  Google Scholar 

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513

Article  CAS  PubMed  Google Scholar 

Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915–2921

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104:1595–1622

Article  PubMed  Google Scholar 

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726–736

Article  CAS  PubMed  Google Scholar 

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195–203

Article  CAS  PubMed  Google Scholar 

Kocjan T, Rajic AS, Janez A, Vidmar G, Orehek N, Marc J, Ostanek B (2021) Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis. Endocr Pract 27:941–947

Article  PubMed  Google Scholar 

Adami S, Martin JS, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87–94

Article  CAS  PubMed  Google Scholar 

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki Ml (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106

Article  CAS  PubMed  Google Scholar 

Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T (2019) Study of twice-weekly injections of teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321–2331

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for Revision of Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis (2012 revised version). Osteoporosis Japan 21:9–21

Google Scholar 

Dudle A, Gugler Y, Pretterklieber M, Ferrari S, Lippuner K, Zysset P (2023) 2D–3D reconstruction of the proximal femur from DXA scans: Evaluation of the 3D-Shaper software. Front Bioeng Biotechnol 1:1111020

Article  Google Scholar 

Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189–199

Article  CAS  PubMed  Google Scholar 

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 19:1147–1155

Article  Google Scholar 

Shin JW, He Q, Suk YJ, Kim SH, Kim HS (2022) Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk. Osteoporos Int 33:2409–2416

Article  CAS  PubMed  Google Scholar 

Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, García M, Del Rio L (2018) Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. Osteoporos Int 29:2323–2333

Article  CAS  PubMed  Google Scholar 

Agarwal S, Shiau S, Kamanda-Kosseh M, Bucovsky M, Kil N, Lappe JM, Stubby J, Recker RR, Guo XE, Shane E, Cohen A (2023) Teriparatide followed by denosumab in premenopausal idiopathic osteoporosis: bone microstructure and strength by HR-pQCT. J Bone Miner Res 38:35–47

Article  CAS  PubMed  Google Scholar 

Chiba K, Okazaki N, Kurogi A, Watanabe T, Mori A et al (2022) Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study. Bone 160:116416

Article  CAS  PubMed  Google Scholar 

Zebaze R, Takao-Kawabata R, Peng Y, Zadeh AG, Hirano K, Yamane H, Takakura A, Isogai Y, Ishizuya T, Seeman E (2017) Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99:80–84

Article  CAS  PubMed  Google Scholar 

Tsukamoto M, Okimoto N, Mori M, Yoshioka T, Asano K, Ikejiri Y, Uzawa T, Yoshimura T, Suzuki H, Yamanaka Y, Kawasaki M, Sakai A (2022) Bone microstructure changes due to once-/twice-weekly teriparatide administration: a report of five cases using high-resolution peripheral quantitative computed tomography. Mod Rheumatol Case Rep 6:301–304

Article  PubMed  Google Scholar 

Takada J, Okimoto N, Tsukamoto M, Akatsuka T, Takebayashi T, Iba K, Ikeda S (2024) Effects of differences in dose and frequency of teriparatide on bone structure in proximal femur. - analysis by DXA-based 3D-modeling (3D-SHAPER software) -TRIPLE-BONE study (the effects of TeRIParatide preparation on bone mineraL density increase and BONE structure). Arch Osteoporos 19:55

Article  PubMed  Google Scholar